TYCHON BIOSCIENCE
Tychon Bioscience is a biotechnology company commercializing adaptive immunotherapy technology. Its PARs harnesses the power of protein dimerization to produce chemically self-assembling nanorings that form a construct to combine a patient’s T-lymphocytes and a host of cancer-seeking antigens creating various cell therapies with selective anti-tumor capabilities.
TYCHON BIOSCIENCE
Industry:
Biopharma Biotechnology Life Science
Founded:
2015-01-01
Address:
Minneapolis, Minnesota, United States
Country:
United States
Website Url:
http://www.tychonbio.com
Total Employee:
11+
Status:
Active
Contact:
+1 612 200 1039
Email Addresses:
[email protected]
Total Funding:
1.62 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt Content Delivery Network Google Apps For Business Amazon Route 53 Typekit Vimeo
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.tychonbio.com Semrush global rank: 6.12 M Semrush visits lastest month: 1.32 K
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Tychon Bioscience" on Search Engine
Tychon
Tychon Biosciences is advancing precision cancer immunotherapy through a novel approach that transforms a patient’s immune cells into a “PAR-T” cell trained to find and …See details»
Tychon Bioscience - Crunchbase Company Profile & Funding
Tychon Bioscience is a biotechnology company commercializing adaptive immunotherapy technology. Its PARs harnesses the power of protein dimerization to produce chemically …See details»
Our Technology Platform — Tychon
Our Technology Platform — Tychon. PAR-T FOR SOLID TUMORS. Globally, translation of immunotherapy to solid tumors has been challenging. At Tychon, we have been focused on solid tumor …See details»
Our Team — Tychon
Arek Z. Dudek, MD, Ph.D. Chief Clinical Specialist Experimental Therapeutics Regions Hospital, HealthPartnersSee details»
Tychon Biosciences | LinkedIn
About us. Tychon Biosciences is a biotechnology company commercializing novel technology in the rapidly expanding Immuno-oncology marketplace that offers similar …See details»
Tychon Biosciences - Products, Competitors, Financials, …
About Tychon Biosciences. Tychon Biosciences focuses on advancing precision cancer immunotherapy in the biotechnology sector. The company's main innovation is a novel …See details»
Tychon Bioscience - Funding, Financials, Valuation & Investors
Organization. Tychon Bioscience. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Funding Rounds 3. Total …See details»
Tychon Bioscience - Crunchbase
Tychon Bioscience is a biotechnology company commercializing adaptive immunotherapy technology.See details»
Invenshure Launches Tychon Biosciences | BioSpace
MINNEAPOLIS, Oct. 13, 2015 /PRNewswire/ -- Venture catalyst Invenshure announces the launch of Tychon Biosciences, a biotechnology company commercializing adaptive …See details»
Invenshure Launches Tychon Biosciences — Invenshure
Oct 13, 2015 MINNEAPOLIS, Minn. – Venture catalyst Invenshure announces the launch of Tychon Biosciences, a biotechnology company commercializing adaptive …See details»
Invenshure Launches Tychon Biosciences™ - PR Newswire
MINNEAPOLIS, Oct. 13, 2015 /PRNewswire/ -- Venture catalyst Invenshure announces the launch of Tychon Biosciences, a biotechnology company commercializing adaptive …See details»
Tychon Bioscience | VentureRadar
Tychon Bioscience is a seed-stage company developing targeted therapeutics and imaging agents for cancer and other diseases. Their products improve patient outcomes …See details»
Tychon Bioscience | VentureRadar
Tychon Bioscience is a seed-stage company developing targeted therapeutics and imaging agents for cancer and other diseases. Their products improve... ... Find out …See details»
Anti-CD133 PARs - Drug Targets, Indications, Patents - Synapse
May 16, 2024 Anti-CD133 PARs: a CD133 inhibitors Drug, Initially developed by Tychon Biosciences LLC, Now, its global highest R&D status is Preclinical, Mechanism: CD133 …See details»
Tychon Bioscience Careers, Perks + Culture | Built In
Jun 20, 2021 Tychon Bioscience is a biotechnology company commercializing adaptive immunotherapy technology. Where We Are. 807 Broadway Street Northeast …See details»
Pipeline — Tychon
Indications. Anti-Epcam PARs. Solid Tumors Breast/Colon. Anti-CD133 PARs. Cancer Stem Cells. Anti-CD19 PARs. Leukemia/ Lymphoma. Universal CAR T-cell. Hybrid CAR/PAR.See details»
Tychon Biosciences - CB Insights
Tychon Biosciences CEO, Founder, Key Executive Team, Board of Directors & Employees. Unclaimed. tychonbio.com. Overview & Products. Financials. People. …See details»
Tychon Bioscience Inc - CAGE.report
May 1, 2013 TYCHON BIOSCIENCE INC DUNS 078303812 / 07-830-3812. NCAGE Code: 6NP16. TYCHON BIOSCIENCE INC. CAGE Code: 6NP16. TYCHON BIOSCIENCE …See details»
Tychon Bioscience - Contacts, Employees, Board Members, …
Organization. Tychon Bioscience. Connect to CRM. Summary Financials People Technology Signals & News Similar Companies. Highlights. Employee Profiles 4. …See details»
Team - iota Biosciences
Meet our leadership team. Michel Maharbiz, PhD. Chief Executive Officer (CEO) Michel cofounded iota Biosciences in 2017. He is a serial entrepreneur and in his spare time …See details»